PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 20, 2013The International Journal of Neuropsychopharmacology77 citationsOpen Access

DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder

View Full Paper
JSJonathan SavitzCHColin A. HodgkinsonCMChantal Martin‐Soelch

Key Points

Key points are not available for this paper at this time.

Abstract

The A1 allele of the DRD2/ANKK1 Taq1A polymorphism (rs1800497) is associated with reduced striatal D(2/3) receptor binding in healthy individuals (Con) as well as depression and addiction. However, the effect of rs1800497 on D(2/3) receptor binding in depressed patients as well as the SNP's effect on D(2/3) binding during reward-associated dopamine release is unknown. Twelve unmedicated patients with major depressive disorder (MDD) and 24 Con completed PET scans with (11)Craclopride, once without receiving monetary rewards (baseline) and once while winning money. In Con, the A1 allele was associated with reduced baseline binding potential (BP(ND)) in the middle caudate and ventral striatum. However, in MDD patients the A1 allele was associated with increased baseline BP(ND) in these regions. There were no significant associations between rs1800497 and change in BP(ND) during reward-associated dopamine release. Conceivably, the A1 allele predisposes to depression and addiction via its effect on the post-synaptic D(2) receptor.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Savitz et al. (2013) studied this question.

synapsesocial.com/papers/69dcfe9cd111c0385b359af5https://doi.org/10.1017/s146114571300045x
Ask AI
Helpful
Bookmark
Share
View Full Paper